share_log

Netcapital | 8-K: Current report

SEC announcement ·  Feb 29 17:15
Summary by Moomoo AI
Netcapital Inc., a company listed on The Nasdaq Capital Market, has received an extension from Nasdaq to meet the minimum bid price requirement for continued listing. The company was initially given until February 28, 2024, to comply with the $1.00 per share minimum bid price rule but failed to do so. On February 29, 2024, Netcapital was granted an additional 180 days, until August 26, 2024, to regain compliance. The extension was based on the company meeting all other listing requirements except for the bid price. Netcapital's common stock will continue to trade under the symbol 'NCPL' during this period. The company may consider a reverse stock split among other options to address the deficiency if the stock price does not meet the requirement within the extended timeframe. If Netcapital fails to comply by the deadline, it risks being delisted from The Nasdaq Capital Market.
Netcapital Inc., a company listed on The Nasdaq Capital Market, has received an extension from Nasdaq to meet the minimum bid price requirement for continued listing. The company was initially given until February 28, 2024, to comply with the $1.00 per share minimum bid price rule but failed to do so. On February 29, 2024, Netcapital was granted an additional 180 days, until August 26, 2024, to regain compliance. The extension was based on the company meeting all other listing requirements except for the bid price. Netcapital's common stock will continue to trade under the symbol 'NCPL' during this period. The company may consider a reverse stock split among other options to address the deficiency if the stock price does not meet the requirement within the extended timeframe. If Netcapital fails to comply by the deadline, it risks being delisted from The Nasdaq Capital Market.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more